Long-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

INTRODUCTION: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era. OBJECTIVES: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaya, Özge, Keskinkaya, Zeynep, Işık Mermutlu, Selda, Oğuz Kılıç, Sevilay, Öztürk, Sevgi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412006/
https://www.ncbi.nlm.nih.gov/pubmed/37557113
http://dx.doi.org/10.5826/dpc.1303a145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412006/
https://www.ncbi.nlm.nih.gov/pubmed/37557113
http://dx.doi.org/10.5826/dpc.1303a145

Ejemplares similares